BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19154412)

  • 41. Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection.
    Abdelbary NH; Abdullah HM; Matsuzaki T; Hayashi D; Tanaka Y; Takashima H; Izumo S; Kubota R
    J Infect Dis; 2011 Apr; 203(7):948-59. PubMed ID: 21402546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant.
    Kozako T; Hirata S; Shimizu Y; Satoh Y; Yoshimitsu M; White Y; Lemonnier F; Shimeno H; Soeda S; Arima N
    FEBS J; 2011 Apr; 278(8):1358-66. PubMed ID: 21332943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Switching and loss of cellular cytokine producing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infection.
    Kagdi H; Demontis MA; Ramos JC; Taylor GP
    PLoS Pathog; 2018 Feb; 14(2):e1006861. PubMed ID: 29444188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
    Kobayashi H; Ngato T; Sato K; Aoki N; Kimura S; Tanaka Y; Aizawa H; Tateno M; Celis E
    Clin Cancer Res; 2006 Jun; 12(12):3814-22. PubMed ID: 16778109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model.
    Nomura M; Ohashi T; Nishikawa K; Nishitsuji H; Kurihara K; Hasegawa A; Furuta RA; Fujisawa J; Tanaka Y; Hanabuchi S; Harashima N; Masuda T; Kannagi M
    J Virol; 2004 Apr; 78(8):3827-36. PubMed ID: 15047798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine.
    Ohashi T; Hanabuchi S; Kato H; Tateno H; Takemura F; Tsukahara T; Koya Y; Hasegawa A; Masuda T; Kannagi M
    J Virol; 2000 Oct; 74(20):9610-6. PubMed ID: 11000233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry.
    Kobayashi S; Watanabe E; Ishigaki T; Ohno N; Yuji K; Nakano K; Yamochi T; Watanabe N; Tojo A; Watanabe T; Uchimaru K
    Cancer Sci; 2015 May; 106(5):598-603. PubMed ID: 25703103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis.
    Ozden S; Cochet M; Mikol J; Teixeira A; Gessain A; Pique C
    J Virol; 2004 Oct; 78(19):10320-7. PubMed ID: 15367598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD69 overexpression by human T-cell leukemia virus type 1 Tax transactivation.
    Ishikawa C; Kawakami H; Uchihara JN; Senba M; Mori N
    Biochim Biophys Acta; 2013 Jun; 1833(6):1542-52. PubMed ID: 23507197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model.
    Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R
    J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CADM1/TSLC1 Identifies HTLV-1-Infected Cells and Determines Their Susceptibility to CTL-Mediated Lysis.
    Manivannan K; Rowan AG; Tanaka Y; Taylor GP; Bangham CR
    PLoS Pathog; 2016 Apr; 12(4):e1005560. PubMed ID: 27105228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals.
    Enose-Akahata Y; Abrams A; Massoud R; Bialuk I; Johnson KR; Green PL; Maloney EM; Jacobson S
    Retrovirology; 2013 Feb; 10():19. PubMed ID: 23405908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation.
    Yuen CK; Chan CP; Fung SY; Wang PH; Wong WM; Tang HV; Yuen KS; Chan CP; Jin DY; Kok KH
    J Virol; 2016 Apr; 90(8):3902-3912. PubMed ID: 26819312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor.
    Sugata K; Yasunaga J; Mitobe Y; Miura M; Miyazato P; Kohara M; Matsuoka M
    Blood; 2015 Aug; 126(9):1095-105. PubMed ID: 26063164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RNF8 Dysregulation and Down-regulation During HTLV-1 Infection Promote Genomic Instability in Adult T-Cell Leukemia.
    Zhi H; Guo X; Ho YK; Pasupala N; Engstrom HAA; Semmes OJ; Giam CZ
    PLoS Pathog; 2020 May; 16(5):e1008618. PubMed ID: 32453758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Saito M; Matsuzaki T; Satou Y; Yasunaga J; Saito K; Arimura K; Matsuoka M; Ohara Y
    Retrovirology; 2009 Feb; 6():19. PubMed ID: 19228429
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of a Unique T Cell Receptor Gene-Transferred Tax-Redirected T Cell Immunotherapy for Adult T Cell Leukemia.
    Kawamura K; Tanaka Y; Nakasone H; Ishihara Y; Kako S; Kobayashi S; Tanaka Y; Ohmori T; Uchimaru K; Okamoto S; Mineno J; Shiku H; Nishimura S; Kanda Y
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1377-1385. PubMed ID: 32311478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from Jamaica.
    Enose-Akahata Y; Abrams A; Johnson KR; Maloney EM; Jacobson S
    Blood; 2012 Mar; 119(12):2829-36. PubMed ID: 22318200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluating mRNA expression of tax, B chain of PDGF and PDGF-β receptors as well as HTLV-I proviral load in ATL patients and healthy carriers.
    Atabati H; Esmaeili SA; Allahyari A; Shirdel A; Rahimi H; Rezaee SA; Momtazi-Borojeni AA; Rafatpanah H
    J Med Virol; 2021 Jun; 93(6):3865-3870. PubMed ID: 32918495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I.
    Goon PK; Igakura T; Hanon E; Mosley AJ; Barfield A; Barnard AL; Kaftantzi L; Tanaka Y; Taylor GP; Weber JN; Bangham CR
    J Immunol; 2004 Feb; 172(3):1735-43. PubMed ID: 14734756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.